What are the Ki‑67 proliferation index and mitotic count cut‑offs used to grade neuroendocrine tumors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Neuroendocrine Tumor Grading Cut-offs

Neuroendocrine tumors are graded using Ki-67 proliferation index and mitotic count with the following cut-offs: Grade 1 (G1) has Ki-67 ≤2% and mitotic count <2 per 10 HPF; Grade 2 (G2) has Ki-67 3-20% and mitotic count 2-20 per 10 HPF; Grade 3 (G3) has Ki-67 >20% and mitotic count >20 per 10 HPF. 1

Standard Grading System

The WHO classification system establishes three distinct grades based on proliferative markers:

Grade 1 (G1) - Low Grade

  • Ki-67 index: ≤2% 1
  • Mitotic count: <2 per 10 high-power fields (HPF) 2
  • These are well-differentiated, low-grade tumors with the most favorable prognosis 2

Grade 2 (G2) - Intermediate Grade

  • Ki-67 index: 3-20% 1
  • Mitotic count: 2-20 per 10 HPF 2
  • These are well-differentiated, intermediate-grade tumors 2

Grade 3 (G3) - High Grade

  • Ki-67 index: >20% 1
  • Mitotic count: >20 per 10 HPF 2
  • These are poorly differentiated, high-grade neuroendocrine carcinomas characterized by aggressive clinical course 2

Critical Technical Considerations

Mitotic Count Assessment

  • Count mitoses in at least 40 fields at 40x magnification in areas of highest mitotic density 2
  • Report as number of mitoses per 10 HPF or per 2 mm² (these are equivalent on most microscopes) 2

Ki-67 Index Determination

  • Report as percentage of positive tumor cells in the area of highest nuclear labeling 2
  • While counting 2000 tumor cells is recommended, estimation is acceptable in routine practice despite reproducibility limitations 2

Discordance Resolution

When mitotic rate and Ki-67 index are discordant, assign the higher grade 2. This is a critical pitfall to avoid—always use the parameter that indicates more aggressive behavior.

Prognostic Significance

Both increased mitotic rate and high Ki-67 index are independently associated with more aggressive clinical course and worse prognosis 2. The grading system has been validated across multiple studies showing:

  • Higher grades correlate with decreased overall survival 2
  • Ki-67 is a strong prognostic factor for both overall survival and disease-free survival 3
  • The combination of these proliferative markers provides optimal prognostic stratification 2

Important Caveats

Site-Specific Variations

While these cut-offs apply broadly to gastroenteropancreatic NETs, some anatomical sites may have slightly different prognostic thresholds 4. For small intestinal NETs specifically, Ki-67 >5% may be more clinically relevant for stage IV disease 4.

Mandatory Reporting

Both Ki-67 immunohistochemistry (MIB-1) and mitotic count are mandatory for all neuroendocrine tumor pathology reports 1. Reporting "neuroendocrine tumor" without grade qualification is inadequate for prognostication and treatment planning 2.

Biopsy Limitations

In small biopsy samples where accurate mitotic rate cannot be determined, Ki-67 index is the preferred method for establishing proliferative rate 2.

References

2
Guideline

neuroendocrine tumors.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Related Questions

What is the recommended treatment for a tumor with a Ki-67 (Proliferation Index) expression of 25% and 3+ intensity?
How should hypotension and bradycardia occurring during an infusion be managed?
What is the significance of mild left atrial enlargement on an otherwise normal transthoracic echocardiogram and how should it be managed?
What are the recommended empiric doses of vancomycin and piperacillin‑tazobactam (Zosyn) for a pregnant woman?
A patient with an acute deep venous thrombosis of the right popliteal, posterior tibial, and gastrocnemius veins who is taking Eliquis (apixaban) incorrectly—does the patient need admission?
How should a suspected false‑positive syphilis screening test be confirmed and what conditions can cause false‑positive results?
Which tool is preferred for assessing appendicitis risk in children and adolescents, the Pediatric Appendicitis Risk Calculator (PARC) or the Appendicitis Inflammatory Response (AIR) score?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.